| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 13
| Issue : 3 | Page : 126-131 |
|
|
Evaluation of tyrosine kinase inhibitor discontinuation initiative in patients with chronic myeloid leukemia at princess noorah oncology center
Afnan Mohammed Noor1, Mansoor Ahmed Khan1, Muteb M Al-Thomali2, Abdelmajid H Alnatsheh1, Ahmed A Absi2, Fahad M Hakami3, Majed A Alshamrani1
1 Department of Pharmaeceutical Care, Ministry of National Guard-Health Affairs, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
2 Department of Haematology, Ministry of National Guard-Health Affairs, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
3 Department of Molecular Medicine, Ministry of National Guard-Health Affairs, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
Correspondence Address:
Dr. Mansoor Ahmed Khan
Department of Pharmaceutical Care, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, P. O. Box: 9515, Jeddah 21423
Saudi Arabia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/joah.joah_144_21
|
|
|
CONTEXT: Tyrosine kinase inhibitors (TKIs) are the standard of care therapy for chronic myeloid leukemia (CML). The current disadvantages of lifelong treatment include adverse effects and financial burden.
AIMS: This study aimed to evaluate the outcomes of treatment-free remission (TFR) in CML patients.
SETTINGS AND DESIGN: A retrospective cohort study was conducted in our oncology center.
SUBJECTS AND METHODS: Patients ≥18 years old diagnosed with CML, received TKI and had a TFR trial to achieve TFR, with at least 6 months follow-up, and who received TKIs were included. Patients with a previous hematopoietic stem cell transplantation were excluded. The primary outcome was the proportion of patients with sustainable TFR at 6 months. The secondary outcomes were the proportion of patients with sustainable TFR at 12 months, the rate of regaining a major molecular response (MMR) after relapse, and the cost-saving impact. Descriptive statistics were used for the demographics and outcomes.
RESULTS: A total of 250 patients were screened for eligibility, 25 patients were enrolled. The median age was 54 years (interquartile range: 45.5–59), 60% were female. TFR was 92% at 6 months and 72% at 12 months. 100% of the patients regained MMR. The total number of TFR days were 17,024 which resulted in a direct cost saving of SR 7,205,601.9, based on Saudi FDA pricing.
CONCLUSIONS: The study indicated that the majority of the CML patients achieved 6 months TFR. This initiative has resulted in a significant cost saving. Future studies should characterize potential candidates for TKI discontinuation.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
